Nirsevimab: all you need to know about the new vaccine against neonatal bronchiolitis

The vaccine is designed to reduce cases of bronchiolitis.Pixel

As fall approaches, cases Bronchiolitis between children. Falling temperatures can exacerbate respiratory and lung infections, mainly affecting children under two years old.To avoid this disease, there are A new vaccine against neonatal bronchiolitis called Nirsevimab. We tell you all about the vaccine with the aim of achieving a significant reduction in the number of cases compared to last year.

Bronchiolitis and RSV

Bronchiolitis affects children younger than two years old. Source: Pexels

Spirit world

This time of year, the presence of respiratory syncytial virus (RSV) becomes common in children. The virus itself is not serious and its symptoms are usually those of a common cold. The problem is when RSV causes complications, The most serious are bronchiolitis and pneumonia

. It is a highly contagious virus, especially between November and March, and although it can affect both children and adults, children under one year old are most at risk of complications such as bronchiolitis.

What is nirumab used for?

It is estimated to use Nirsevimab Bronchiolitis cases reduced by up to 80% in infants and has been administered for this purpose. Its use was approved by the Public Health Commission last May and good results are expected in the coming months.

In fact, nirumab This is not a common vaccine, which also does not specifically prevent bronchiolitis, but targets the virus that causes bronchiolitis, RSV. It is a protein that detects and binds to viruses to “seal” them. This way, it can’t open up and infect any cells.

To whom is Nirsevimab administered?

{{ #cards }}

{{#section.link.href}} {{section.link.title}} {{/section.link.href}}

{{title.data}}

{{/card}}

It is suitable for children under six months of age and newborns. Source: PexelsSpirit world

It is understood that the high-risk period for RSV begins at the end of October.He will probably have been vaccinated by then. children under six months. It will continue to be given to all babies born until March, when it starts to wear off. The administration of Nirsevimab depends on each autonomous region, so the competent regional organization will be responsible for informing parents that it is time to inject their children.

How long is the vaccine effective?

so far Proven effective in preventing viruses Six months. That’s why it’s used in newborns and children under six months of age, because at this age, their immune systems are less able to fight off RSV. After half a year of life, the body has the ability to deal with the virus naturally.